Invivyd (IVVD) Asset Utilization Ratio (2024 - 2025)
Invivyd (IVVD) reported Asset Utilization Ratio of 0.26 for Q4 2025, up 47.44% on a YoY basis from 0.17 in Q4 2024, and down 41.41% quarter-over-quarter from 0.44 in Q3 2025.
Invivyd (IVVD) Asset Utilization Ratio (2024 - 2025) Analysis & Trends
Invivyd has reported Asset Utilization Ratio for 2 years, with the latest figure at 0.26 in Q4 2025.
- For the quarter ending Q4 2025, Asset Utilization Ratio rose 47.44% year-over-year to 0.26; the trailing twelve-month figure through Dec 2025 stood at 0.26 (up 47.44% YoY), and the FY2025 full-year result was 0.26, up 85.77% from the prior year.
- Asset Utilization Ratio for Q4 2025 stood at 0.26, down from 0.44 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.48 in Q2 2025, with the low at 0.01 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 0.55 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.60 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 1,422.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - | 0.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.26 |
| Sep 30, 2025 | 0.44 |
| Jun 30, 2025 | 0.48 |
| Mar 31, 2025 | 0.31 |
| Dec 31, 2024 | 0.17 |
| Sep 30, 2024 | 0.07 |
| Jun 30, 2024 | 0.01 |